Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: Durvalumab|DRUG: Tremelimumab
≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1, From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 29 months
≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 2, From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 29 months|Overall Survival (OS), From the first dose of treatment to the date of death, regardless of the actual cause of the subject's death, assessed up to 29 months|Progression Free Survival (PFS) per RECIST v1.1/mRECIST, From first dose of treatment until progression per RECIST 1.1/ mRECIST as assessed by the Investigator or death due to any cause prior to progression, assessed up to 15 months|Objective Response Rate (ORR) per RECIST 1.1/ mRECIST, Until progression, assessed up to 15 months|Disease Control Rate (DCR) per RECIST 1.1/ mRECIST, Until progression, assessed up to 15 months|Rate of Adverse Events, From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 29 months|Duration of response (DoR) per RECIST 1.1/mRECIST, From the first dose, until progression, assessed up to 15 months
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.